Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMJGleeson Regulatory News (GLE)

Share Price Information for MJGleeson (GLE)

Share Price is delayed by 15 minutes
Get Live Data
240.00    1.00 (0.42%)
Bid:
237.50
Ask:
239.50
Spread: 2.00 (0.842%)
Market Cap: £140.01m
GLE Live PriceLast checked at - London Stock Exchange

Intraday MJGleeson Share Chart

AGM Trading Update

15 Nov 2024 07:00

RNS Number : 3422M
MJ Gleeson PLC
15 November 2024
 

MJ Gleeson plc  (GLE.L)

 

AGM Trading Update

15 November 2024

MJ Gleeson plc, the low-cost housebuilder and land promoter, is issuing the following update ahead of its Annual General Meeting which is being held later today.

As previously indicated, and for the reasons set out below, the results for the financial year will be more weighted to the second half than usual. The Board continues to expect that the results for the year will be in line with current market expectations1.

Gleeson Homes

As anticipated, the lack of conviction in the market continued through the Autumn. Last week's base rate reduction was welcome and is expected to bolster buyer confidence into the important Spring selling season.

Net reservation rates for the period 1 July to 1 November 2024 increased to 0.56 per site per week (0.47 excluding bulk reservations), from the 0.45 per site (0.41 excluding bulk reservations) during the same period last year.

Gleeson Homes continues to experience margin pressure as a result of the use of higher sales incentives, the impact of multi-unit sales, increased build costs and limited relief from increasing selling prices.

Gleeson Homes has commenced its programme of new site openings, having already opened 7 new sales sites this financial year. The division expects to open a total of 27 sales sites during the year (FY2024: 4 sales sites opened), but will be selling overall on a lower average number of sites than last year, with fewer sites in H1 than H2. Gleeson Homes will continue the positive momentum of site openings from FY2026 targeting a net 10 new sales sites per year.

As the wider market improves, we remain confident in Gleeson Homes' ability to fulfil this ambitious programme of site openings which will drive the exciting sector-leading growth planned for FY2026 and beyond.

Gleeson Land

Gleeson Land continues to promote several exciting opportunities. The prospective reform of the National Planning Policy Framework is expected to beneficially impact the timing of certain sites. 

Strong demand for consented land from large and medium-sized developers continues to give the Board confidence that Gleeson Land will deliver a full year result materially ahead of last year, with a number of significant sales expected to be completed in H2.

A Trading Update for the 6 months to 31 December 2024 will be issued on 14 January 2025.

 

1 Analyst consensus for FY2025 can be found at: https://www.mjgleesonplc.com/investors/analyst-coverage/

 

 

 

The information contained within this announcement was previously deemed by the Company to constitute inside information as stipulated by Market Abuse Regulation (EU) No 596/2014 ("EU MAR") and the retained UK law version of EU MAR pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019 (SI 2019/310) ("UK MAR"). With the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain. For the purposes of UK MAR, the person responsible for arranging for the release of this information on behalf of MJ Gleeson plc is Stefan Allanson, Chief Financial Officer

LEI: 21380064K7N2W7FD6434

Enquiries:

 

MJ Gleeson plc

 +44 1142 612 900

Graham Prothero Chief Executive Officer

Stefan Allanson Chief Financial Officer

Hudson Sandler

+44 207 796 4133 / gleeson@hudsonsandler.com

Mark Garraway

Harry Griffiths

 

Singer Capital Markets

+44 20 7496 3000

Shaun Dobson

Charles Leigh-Pemberton

Investec

+44 207 597 4000

Ben Griffiths

Tom Brookhouse

  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKQBBDBDBKDD
Date   Source Headline
10th Feb 20227:00 amRNSHalf-year Report
8th Feb 20224:20 pmRNSDirector/PDMR Shareholding
11th Jan 20224:38 pmRNSDirector/PDMR Shareholding
11th Jan 20227:00 amRNSNotice of Results & Trading Update
31st Dec 20217:00 amRNSTotal Voting Rights
8th Dec 20212:47 pmRNSDirector/PDMR Shareholding
30th Nov 20217:00 amRNSTotal Voting Rights
26th Nov 20214:50 pmRNSDirector/PDMR Shareholding - Amendment
26th Nov 20214:49 pmRNSDirector/PDMR Shareholding
15th Nov 202112:52 pmRNSResult of AGM
15th Nov 20217:00 amRNSAGM Statement
8th Nov 20211:50 pmRNSDirector/PDMR Shareholding
4th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20218:29 amRNSDirector/PDMR Shareholding
29th Oct 20217:00 amRNSTotal Voting Rights
26th Oct 20219:38 amRNSDirector/PDMR Shareholding
15th Oct 20214:41 pmRNSSecond Price Monitoring Extn
15th Oct 20214:36 pmRNSPrice Monitoring Extension
13th Oct 202112:48 pmRNSNotice of AGM
8th Oct 20211:22 pmRNSDirector/PDMR Shareholding
1st Oct 20217:00 amRNSPerformance Share Plan award to PDMRs
30th Sep 20217:00 amRNSTotal Voting Rights
28th Sep 20214:09 pmRNSPerformance Share Plan award to Directors
28th Sep 20214:06 pmRNSDirector/PDMR Shareholding
15th Sep 202110:33 amRNSDirector/PDMR Shareholding - Amendment
14th Sep 20217:00 amRNSAudited results for the year ended 30 June 2021
8th Sep 202111:14 amRNSDirector/PDMR Shareholding
31st Aug 20217:00 amRNSTotal Voting Rights
9th Aug 20214:37 pmRNSPrice Monitoring Extension
9th Aug 20211:11 pmRNSDirector/PDMR Shareholding
30th Jul 20217:00 amRNSTotal Voting Rights
21st Jul 20217:00 amRNSLong Term Incentive Plan award to Director
9th Jul 20219:41 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSNotice of Results & Trading Update
7th Jul 20214:47 pmRNSDirector/PDMR Shareholding
30th Jun 20217:00 amRNSTotal Voting Rights
8th Jun 20214:44 pmRNSDirector/PDMR Shareholding
28th May 20217:00 amRNSTotal Voting Rights
24th May 20217:00 amRNSTrading Update
7th May 20214:33 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSTotal Voting Rights
9th Apr 20212:02 pmRNSDirector/PDMR Shareholding
31st Mar 20217:00 amRNSTotal Voting Rights
26th Mar 20214:08 pmRNSRe Committee appointments
22nd Mar 20218:34 amRNSPerformance Share Plan award to Directors/PDMRs
8th Mar 20211:44 pmRNSDirector/PDMR Shareholding
1st Mar 20217:00 amRNSRe Directorate
26th Feb 20217:00 amRNSTotal Voting Rights
11th Feb 20217:00 amRNSHalf-year Report
8th Feb 20215:07 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.